- Autolus Therapeutics plc's AUTL Phase 2 pivotal FELIX trial of obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) adult Acute Lymphoblastic Leukemia (ALL) has met its primary endpoint of Overall Remission Rate (ORR).
- The data comes from a pre-planned interim analysis of 50 patients.
- The ORR for obe-cel was 70%. Obe-cel showed comparable expansion and initial persistence (median follow-up 6.4 months) to the data observed in the prior ALLCAR19 study.
- The safety analysis was based on 92 patients treated with obe-cel and evaluable for safety.
- The company observed that 3% of patients experienced Grade 3 or higher CRS, 8% experienced Grade 3 or higher ICANS, and 23% experienced any grade ICANS.
- Autolus plans to present the results from the FELIX trial, with a longer follow-up planned to be reported at the end of 2023.
- Blackstone Life Sciences has committed two pre-agreed milestone payments of $70 million to Autolus due to the interim analysis of the FELIX Phase 2 trial.
- Concurrently, Autolus has priced 75 million ADSs representing 75 million shares at $2.00 per ADS, for total gross proceeds of $150 million.
- Underwriters have the option to purchase up to an additional 11.25 million ADSs.
- Price Action: AUTL shares closed 29.10% lower at $2.12 during premarket trading on the last check Friday.
Loading...
Loading...
AUTLAutolus Therapeutics PLC
$2.06-%
Edge Rankings
Momentum
14.77
Growth
Not Available
Quality
Not Available
Value
8.36
Price Trend
Short
Medium
Long
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
